Anthelmintic activity of lapachol, β-lapachone and its derivatives against Toxocara canis LARVAE;Atividade anti-helmíntica do lapachol, β-lapachona e derivados contra Larvas de Toxocara canis

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 57, Issue 3, 2015, Pages 197-204

  Mata Santos, Taís ^a   Pinto, Nitza França ^a   Mata Santos, Hilton Antônio ^b   De Moura, Kelly Gallan ^b   Carneiro, Paula Fernandes ^b   Carvalho, Tatiane dos Santos ^b   Del Rio, Karina Pena ^b   Pinto, Maria do Carmo Freire Ribeiro ^b   Martins, Lourdes Rodrigues ^a   Fenalti, Juliana Montelli ^a   Da Silva, Pedro Eduardo Almeida ^a   Scaini, Carlos James ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Anthelmintics; Chemotherapy; Quinones; Toxocara canis

Indexed keywords

BETA C ALLYL LAWSONE; BETA LAPACHONE; LAPACHOL; PHENAZINE DERIVATIVE; PLANT EXTRACT; TABEBUIA EXTRACT; UNCLASSIFIED DRUG; ANTHELMINTIC AGENT; BETA-LAPACHONE; NAPHTHOQUINONE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHELMINTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; FEMALE; HELMINTHIASIS; IN VITRO STUDY; LARVA; MINIMUM LARVICIDAL CONCENTRATION; MOUSE; NONHUMAN; PARASITE VIABILITY; PHARMACOLOGICAL PARAMETERS; TABEBUIA; TOXOCARA CANIS; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SENSITIVITY; GROWTH, DEVELOPMENT AND AGING;

ANIMALS; ANTHELMINTICS; FEMALE; LARVA; MICE; MICE, INBRED BALB C; NAPHTHOQUINONES; PARASITIC SENSITIVITY TESTS; TOXOCARA CANIS;

EID: 84937697862     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/S0036-46652015000300003     Document Type: Article

References (40)

1. Abo-Shehada MN, Herbert IV. The migration of larval Toxocara canis in mice. II. Postintestinal migration in primary infections. Vet Parasitol. 1984;17:75-83.
2. Coelho TS, Silva RS, Pinto AV, Pinto MC, Scaini CJ, Moura KC, et al. Activity of β-lapachone derivatives against rifampicin-susceptible and–resistant strains of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2010;90:293-7.
3. Da Silva MN, Ferreira VF, De Souza MCBV. Um panorama atual da química e da farmacologia de naftoquinonas, com ênfase na β-Lapachona e derivados. Química Nova. 2003;26:407-16.
4. De Almeida ER, da Silva Filho AA, dos Santos ER, Lopes CA. Antiinflammatory action of lapachol. J Ethnopharmacol. 1990;29:239-41.
5. De Andrade-Neto VF, Goulart MOF, da Silva Filho JF, da Silva MJ, Pinto MC, Pinto AV, et al. Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo. Bioorg Med Chem Lett. 2004;14:1145-9.
6. Delgado O, Botto C, Mattei R, Escalante A. Effect of albendazole in experimental toxocariasis of mice. Ann Trop Med Parasitol. 1989;83:621-4.
7. De Moura KCG, Emery FS, Neves-Pinto C, Pinto MCFR, Dantas AP, Salomão K, et al. Trypanocidal activity of isolated naphthoquinones from Tabebuia and some heterocyclic derivatives: a review from an interdisciplinary study. J Braz Chem Soc. 2001;12:325-38.
8. De Moura KCG, Salomão K, Menna-Barreto RF, Emery FS, Pinto MC, Pinto AV, et al. Studies on the trypanocidal activity of semi-synthetic pyran[b-4,3]naphtho[1,2-d] imidazoles from b-lapachone. Eur J Med Chem. 2004;39:639-45.
9. Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. Clin Microbiol Rev. 2003;16:265-72.
10. Dubin M, Fernandez-Villamil SH, Stoppani AO. Cytotoxicity of β-lapachone, an o-naphthoquinone with possible therapeutic use. Medicina (B Aires). 2001;61:343-50.
11. Ettlinger MG. Hydroxynaphthoquinones. III. The structure of lapachol peroxide. J Am Chem Soc. 1950;72:3472-4.
12. Falkenberg, MB. Quinonas. In: Simões CMO, Schenkel EP, Gosmann G, Mello JCP, Mentz LA, Petrovick PR, editors. Farmacognosia: da planta ao medicamento. Porto Alegre: Ed. UFRGS; 2004. p. 1102.
13. Fan CK, Liao CW, Cheng YC. Factors affecting disease manifestation of toxocarosis in humans: genetics and environment. Vet Parasitol. 2013;193:342-52.
14. Fieser LF, Fieser M. Naphthoquinone antimalarials. XII. The hooker oxidation reaction. J Am Chem Soc. 1948;70:3215-22.
15. Glickman LT, Schantz PM, Cypess RH. Canine and human toxocariasis: review of transmission, pathogenesis, and clinical disease. J Am Vet Med Assoc. 1979;175:1265-9.
16. Hooker SC. Lomatiol. Part II. Its occurrence, constitution, relation to and conversion into lapachol. Also a synthesis of lapachol. J Am Chem Soc. 1936;58:1181-90.
17. Hooker SC. The constitution of lapachol and its derivatives. Part IV. Oxidation with potassium permanganate. J Am Chem Soc. 1936;58:1168-73.
18. Hotez PJ, Wilkins PP. Toxocariasis: America’s most common neglected infection of poverty and a helminthiasis of global importance? PLOS Negl Trop Dis. 2009;3:400.
19. Hussain H, Krohn K, Ahmad VU, Miana GA, Green IR. Lapachol: an overview. Arkivoc. 2007;2:145-71.
20. Hussain H, Specht S, Sarite SR, Saeftel M, Hoerauf A, Schulz B, et al. A new class of phenazines with activity against a chloroquine resistant Plasmodium falciparum strain and antimicrobial activity. J Med Chem. 2011;54:4913-7.
21. Laursen JB, Nielsen J. Phenazine natural products: biosynthesis, synthetic analogues and biological activity. Chem Rev. 2004;104:1663-85.
22. Lescano SZ, Chieffi PP, Amato Neto V, Ikai DK, Ribeiro MCSA. Anthelmintics in experimental toxocariasis: effects on larval recovery of Toxocara canis and on immune response. J Bras Patol Med Lab. 2005;41:21-4.
23. Lima NMF, Correia CS, Leon LL, Machado GMC, Madeira MF, Santana AEG, et al. Antileishmanial activity of lapachol analogues. Mem Inst Oswaldo Cruz. 2004;99:757-61.
24. Lopes JN, Cruz FS, Docampo R, Vasconcellos ME, Sampaio MC, Pinto AV, Gilbert B. In vitro and in vivo evaluation of the toxicity of 1,4-naphthoquinone and 1,2-naphthoquinone derivatives against Trypanosoma cruzi. Ann Trop Med Parasitol. 1978;72:523-31.
25. Magnaval JF. Comparative efficacy of diethylcarbamazine and mebendazole for the treatment of human toxocariasis. Parasitology. 1995;110:529-33.
26. Maizels RM. Toxocara canis: molecular basis of immune recognition and evasion. Vet Parasitol. 2013;193:365-74.
27. Nunes CM. Imunodiagnóstico da larva migrans visceral através de um método de ELISA indireto competitivo. [Tese]. São Paulo: Universidade de São Paulo, Faculdade de Medicina Veterinária e Zootecnia; 1996.
28. Othman AA. Therapeutic battle against larval toxocariasis: are we still far behind? Acta Trop. 2012;124:171-8.
29. Pardee AB, Li YZ, Li CJ. Cancer therapy with beta-lapachone. Current Cancer Drug Targets. 2002;2:227-42.
30. Pawlowski Z. Toxocariasis in humans: clinical expression and treatment dilemma. J Helminthol. 2001;75:299-305.
31. Quattrocchi G, Nicoletti A, Marin B, Bruno E, Druet-Cabanac M, Preux PM. Toxocariasis and epilepsy: systematic review and meta-analysis. PLOS Negl Trop Dis. 2012;6:1775.
32. Reis M, Trinca A, Ferreira MJ, Monsalve-Puello AR, Grácio MAA. Toxocara canis: potential activity of natural products against second-stage larvae in vitro and in vivo. Exp Parasitol. 2010;126:191-7.
33. Satou T, Horiuchi A, Akao N, Koike K, Futja K, Nikaido T. Toxocara canis: search for a potential drug amongst β-carboline alkaloids - in vivo and mouse studies. Exp Parasitol. 2005;110:134-9.
34. Schneier AJ, Durand ML. Ocular toxocariasis: advances in diagnosis and treatment. Int Ophthalmol Clin. 2011;51:135-44.
35. Silva RSF. Síntese de fenazinas e derivados lactônicos e halogenados a partir de naftoquinonas naturais com atividade contra Mycobacterium tuberculosis. [Tese]. Rio de Janeiro: Universidade Federal do Rio de Janeiro, Núcleo de Pesquisa de Produtos Naturais; 2009.
36. Smith H, Holland C, Taylor M, Magnaval JF, Schantz P, Maizels R. How common is human toxocariasis? Towards standardizing our knowledge. Trends Parasitol. 2009;25:182-8.
37. Stürchler D, Schubarth P, Gualzata M, Gottstein B, Oettli A. Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial. Ann Trop Med Parasitol. 1989;83:473-8.
38. Torrado S, Torrado S, Cadorniga R, Torrado JJ. Formulation parameters of albendazole solution. Int J Pharm. 1996;140:45-50.
39. Wang GX, Luo ZJ. A novel method for the recovery of Toxocara canis in mice. J Helminthol. 1998;72:183-4.
40. Wisniewska-Ligier M, Wozniakowska-Gesicka T, Sobolewska-Drylariska J, Markiewicz-Jógwiak A, Wieczorek M. Analysis of the course and treatment of toxocariasis in children: a long term observation. Parasitol Res. 2012;110:2363-71.